经皮穿刺注射博来霉素硬化治疗肝血管瘤  被引量:2

Percutaneous injection of bleomycin for the treatment of hepatic hemangiomas

在线阅读下载全文

作  者:李建柯 石红建[1] 沈涛[1] 徐强[1] 黄优华[1] LI Jian-ke;SHI Hong-jian;SHEN Tao;XU Qiang;HUANG You-hua(Department of Changzhou Wujin People's Hospital,Jiangsu Changzhou vascular interventional,213017)

机构地区:[1]常州市武进人民医院介入血管科,江苏常州213017

出  处:《临床医药文献电子杂志》2017年第67期13082-13083,13085,共3页Electronic Journal of Clinical Medical Literature

基  金:常州市科技局应用基础研究计划(20160002)

摘  要:目的观察CT引导下经皮穿刺注射博来霉素硬化治疗肝血管瘤的有效性及安全性。方法选取我院2015年02月~2016年07月收治的肝血管瘤患者11例采取CT引导下经皮穿刺注射博来霉素治疗,分别于术后3月、6月、1年观察患者的临床症状变化、瘤体变化情况、术后近期及远期并发症。结果 11例患者均成功完成经皮穿刺硬化治疗,CR2例、PR9例,无进展病例,有效率达100%。术后出现恶心呕吐5例,上腹部隐痛3例,发热1例,对症处理后症状消失,无严重并发症。结论 CT引导下经皮穿刺注射博来霉素硬化治疗肝血管瘤是一种安全有效的介入治疗方法,值得在临床上推广应用。Objective To observe the effectiveness and safety of percutaneous injection of bleomycin under CT guidance for the treatment of hepatic hemangioma.Methods 07 patients with hepatic hemangioma admitted in our hospital from 02 months to 2016 2015 were treated with CT guided percutaneous injection of bleomycin 11 cases,All the patients were followed up for 12 months with color ultrasound or CT scanning to determine the tumor's size.After the treatment the patient’s clinical condition was evaluated and the occurrence of untoward reactions was recorded.Results All patients received successful treatment,Complete remission(CR)was achieved in 2 cases,partial remission(PR)in 9 cases,No progress cases.The adverse effects included nausea with vomiting(n=5),upper abdominal pain with dyspnea(n=3),fever(n=1),all of which disappeared after symptomatic treatment.No serious complications.Conclusion Percutaneous injection of bleomycin under CT guidancethe in treatment of hepatic hemangioma is a safe and effective interventional therapy,It is worth to further promote the clinical application.

关 键 词:肝血管瘤 经皮穿刺硬化 博来霉素 

分 类 号:R735.7[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象